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ABSTRACT Bronchial thermoplasty is a treatment for asthma. It is currently unclear whether its
histopathological impact is sufficiently explained by the proportion of airway wall that is exposed to
temperatures necessary to affect cell survival.
Airway smooth muscle and bronchial epithelial cells were exposed to media (37–70°C) for 10 s to
mimic thermoplasty. In silico we developed a mathematical model of airway heat distribution post-
thermoplasty. In vivo we determined airway smooth muscle mass and epithelial integrity pre- and post-
thermoplasty in 14 patients with severe asthma.
In vitro airway smooth muscle and epithelial cell number decreased significantly following the addition
of media heated to ⩾65°C. In silico simulations showed a heterogeneous heat distribution that was
amplified in larger airways, with <10% of the airway wall heated to >60°C in airways with an inner radius
of ∼4 mm. In vivo at 6 weeks post-thermoplasty, there was an improvement in asthma control (measured
via Asthma Control Questionnaire-6; mean difference 0.7, 95% CI 0.1–1.3; p=0.03), airway smooth muscle
mass decreased (absolute median reduction 5%, interquartile range (IQR) 0–10; p=0.03) and epithelial
integrity increased (14%, IQR 6–29; p=0.007). Neither of the latter two outcomes was related to improved
asthma control.
Integrated in vitro and in silico modelling suggest that the reduction in airway smooth muscle post-
thermoplasty cannot be fully explained by acute heating, and nor did this reduction confer a greater
improvement in asthma control.
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Introduction
Bronchial thermoplasty (BT) is a non-pharmacological therapy for treating severe asthma by selectively
heating conductive airways (3–10 mm in diameter) from within the lumen with a low-power electrical
current [1, 2]. During the BT procedure, thermal energy is delivered to the airway wall via a
bronchoscope-inserted catheter with a distal basket of four electrodes that expand to make contact with
the airway wall, aiming to reach a target temperature of 65°C for 10 s.
The primary target of BT is the airway smooth muscle (ASM), a key contributor to airway remodelling,
particularly in severe asthma [2–7]. Previous animal studies demonstrated a reduction in airway
hyper-responsiveness and an altered ASM histological appearance following BT [8]. Subsequent clinical
trials showed improved quality of life and reduced frequency of severe exacerbations in those receiving BT
versus a sham procedure, but found no significant difference in lung function as a result of the treatment
[9–12]. In uncontrolled observational studies, BT has been associated with an ∼50–80% relative loss of
ASM mass determined by bronchial biopsies [13–16], which were typically obtained 1–3 months after
completion of the BT procedures. Although thermal ablation by radiofrequency energy is commonly used
in surgical practice [17, 18], there is a paucity of theoretical [19] and in vitro [20] studies in humans that
assess the direct effect of supra-febrile temperatures on ASM cells’ survival and function, or the early
effects of BT upon ASM mass and epithelial integrity.
We hypothesised that during BT the proportion of the airway exposed to temperatures necessary to affect
ASM and epithelial cell survival, determined from in vitro experiments, is sufficient to explain the impact
of BT. To test our hypothesis we employed in vitro, in silico and in vivo methodologies to define the acute
impact of BT on ASM and epithelial cells.
Methods
Detailed methods are included in the supplementary material.
In vitro heating of human primary ASM, epithelial cells and bronchial epithelial cells
Primary ASM and epithelial cells were cultured as described previously [21]. The study was approved by
the Leicestershire Research Ethics Committee (REC 08/H0406/189). Informed consent was obtained from
all subjects. The human bronchial epithelial cells (hBECs) were obtained from LGC Standards (Middlesex,
UK).
Cells were grown to confluence in 6- or 24-well plates, then exposed to heated media for 10 s using the
protocol described in the supplementary methods. Heat loss over the 10-s period was measured and
showed that following the addition of media heated to 65°C, cells were exposed to a mean temperature of
58–59°C in both 6- and 24-well plates (supplementary table S4).
The number of remaining adherent viable cells up to 2 weeks post-heating was assessed using PrestoBlue®
(Thermo Fisher Scientific, Warrington, UK) according to manufacturer’s instructions and confirmed at
specified times by cell counts. The percentage of the remaining adherent cell population undergoing
apoptosis or necrosis 24 h post-heating was determined using the Alexa Fluor® 488 Annexin V/Dead Cell
Apoptosis Kit (Thermo Fisher Scientific) as described previously [22]. Fluorescence emission was collected
at 530 nm (Annexin V) and >575 nm (propidium iodide) on a flow cytometer and the percentage of
apoptotic and necrotic cells derived respectively using WEASEL™ software (Frank Battye Flow Cytometry
Consulting, Melbourne, Australia).
In silico bioheat mathematical modelling
Because it is not currently possible to measure the heat transfer within the airway wall during BT in vivo,
a two-dimensional mathematical model was developed that couples Joule heating due to the electrical
current generated by the BT electrodes (with integrated temperature control feedback, similar to [19]) with
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the bioheat transfer in the airway wall and surrounding parenchymal tissue. The material properties of the
lung were applied to the model as shown in supplementary table S1. The coupled model was implemented
using the finite element-based modelling framework of COMSOL Multiphysics® 5.2 (Stockholm, Sweden).
Heat maps were integrated over the airway wall to characterise heating pattern heterogeneity.
Local sensitivity analysis was conducted to identify key geometric, physiological and equipment
parameters, and to test the robustness of model predictions. Mathematical model formulation and further
technical details can be found in the supplementary material. The mathematical model was validated using
the in vitro data on the cooling of heated media in multi-well plates (see the in vitro methods above),
which showed good agreement (supplementary figure S3).
The predicted distribution of temperatures in the airway wall, in combination with the thermal
dose-dependent response of ASM and bronchial epithelial cells in vitro, was used to estimate the overall acute
impact of BT on the bronchial wall (the modelling framework is illustrated in supplementary figure S1).
In vivo response to BT
Bronchial biopsies were obtained from 14 subjects before and after BT. All subjects had severe asthma as
defined by American Thoracic Society/European Respiratory Society guidelines, and underwent BT as part
of their clinical care.
BT was performed as per manufacturer’s guidelines over three staged treatment sessions in the following
order: right lower lobe, left lower lobe, and both right and left upper lobes. The right middle lobe was not
treated owing to the risk of airway collapse and “right middle lobe syndrome” [23]. Biopsies were obtained
from the untreated right upper lobe at the first BT session and the treated right lower lobe segmental and
subsegmental airways at the second BT session.
Biopsies were embedded in paraffin and 4-μm sections stained with haematoxylin and eosin or
anti-α-smooth muscle actin (α-SMA, clone 1A4; Dako, Stockport, UK). Biopsies were assessed by a single
observer (RJR) blinded to clinical characteristics to determine 1) the ASM content as a percentage of total
biopsy area; 2) the epithelial integrity by measuring and expressing the length of intact, damaged and
denuded epithelium as a percentage of reticular basement membrane length; and 3) the number of
myofibroblasts (isolated α-SMA-positive stained cells in the lamina propria that were neither located as part
of the ASM bundle nor as vascular smooth muscle cells adjacent to vessels) per mm2 of lamina propria.
Statistical analysis
The statistical analysis is discussed in more detail in the supplementary methods. Briefly, data were
analysed in GraphPad Prism® 7.0 and R project 3.2.4, using parametric and non-parametric tests as
appropriate. Confidence intervals for the medians of cell counts were estimated using the bootstrap
percentile method (R boot package). A p-value <0.05 was considered statistically significant.
Results
In vitro apoptosis and necrosis of ASM and hBEC cells
A metabolic assay demonstrated that the addition of media heated to 65°C or 70°C for 10 s, but not 45–60°
C, resulted in a significant reduction in the number of ASM and hBEC cells remaining adherent after 24 h
compared to 37°C (figure 1a, b). This reduction in the number of viable (metabolically active) adherent cells
persisted over 2 weeks after the addition of media heated to 65°C or 70°C for ASM and to 70°C for hBEC
cells compared to 37°C. The number of viable hBEC cells recovered, such that 10 days after the addition of
media heated to 65°C their numbers were not significantly reduced versus 37°C (figure 1a–d). The results
presented in figure 1a–d were confirmed at various times using cell counts (figure 1e, f), which supported the
results of the metabolic assay. There was a significant reduction in ASM and hBEC cell counts after the
addition of media heated to 65°C at 24–48 h (data not shown), which persisted for 1 week (figure 1e) and
2 weeks (data not shown) for ASM, with a recovery of hBEC cell number after 1 week (figure 1f). In addition
to the reduction in ASM and hBEC cell number post-addition of media heated to 65°C or 70°C versus 37°C,
there was a significant increase in the percentage of cells undergoing necrosis, but not apoptosis (figure 1g, h)
in the remaining adherent cell population after 24 h. The median of the relative reduction in viable ASM cell
number after the addition of media heated to 65°C at 24 h was 60% (95% bootstrap CI 40–80%).
In silico heating heterogeneity profiles
Our computational finite element-based model implementing the BT protocol showed a high degree of
temperature variation over an airway wall. An example with reference model geometry (inner and outer
wall radii of 2.2 and 3.3 mm, respectively) is shown in figure 2. To assess the impact each of the
parameters in the mathematical model had on heat distribution, we undertook a local sensitivity analysis
(supplementary material). This demonstrated that the model predictions were relatively insensitive to the
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FIGURE 1 Response of in vitro heated airway smooth muscle (ASM) and human bronchial epithelial (hBEC) cells. a, b) Representative cell
morphology for cultures following addition of media heated to 65°C; note the incomplete recovery of ASM (a) compared to hBEC (b) cells over
2 weeks. Scale bar, 0.1 mm. c, d) Longitudinal viability of ASM (c) and hBEC (d) cells following addition of media heated to specified temperatures
(mean±SE). e, f ) Total cell count relative to 37°C-matched control 1 week after the addition of heated media for ASM (e) and hBEC (f ) cells. g, h)
Proportion of apoptotic and necrotic ASM (g) and hBEC (h) cells determined by flow cytometry 24 h after the addition of media heated to specified
temperatures (mean, 95% CI). *p<0.05, **p<0.01, ***p<0.001 versus 37°C controls.
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tissue material properties and heating control parameters (supplementary table S3), but strongly
dependent on the airway calibre and wall thickness (supplementary table S3 and figure S2). This
amplification of temperature variation in the larger airways is shown in figure 3, demonstrating only a
small fraction of the wall heated to 65°C (figure 3 and table 1).
Although energy transfer is more efficient in the smallest airways accessible to a BT catheter (figure 3a),
suboptimal heating is possible in the case of an occluded airway with reduced luminal cooling (figure 3b),
and heating heterogeneity is strongly exacerbated in larger airways (figure 3c). Our model suggests that
<5% of a typical airway (internal radius ∼4 mm) treated with BT is exposed to temperatures >65°C, and
<10% to temperatures >60°C (table 1). Post-BT thermal equilibration does not improve the extent of
heating in the upper temperature range, with no portion of the wall experiencing temperatures >65°C in
the 1–2 s after the end of energy delivery (figure 3d, e), even when there is no volumetric cooling due to
tissue perfusion and alveolar moisture evaporation. Therefore, only a small percentage of the area of
airways treated with BT are likely to be exposed to temperatures >60°C, except for the smallest treated
airways. Owing to the accessibility of the airways with a bronchoscope, those airways biopsied were
proximal to the smallest airways treated with BT.
In vivo BT impact on ASM mass and epithelial integrity
The baseline and follow-up clinical characteristics of the 14 subjects are shown in table 2. Nine subjects
were receiving treatment with regular systemic corticosteroids (Global Initiative for Asthma (GINA)
step 5) and the remaining subjects were receiving GINA step 4 treatment. Six weeks after the last BT
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FIGURE 2 Characterisation of bronchial thermoplasty (BT) heating patterns. a) Reference model geometry
(inner wall radius of 2.2 mm, outer radius of 3.3 mm). b) Heat map at the end of a single BT activation (10 s).
c) Temporal dynamics of the applied voltage (red), electrode temperature (solid blue) and temperature at the
midpoint between two electrodes (dashed green; marked by a white dot in b). d) Distribution of heated wall
area fractions, corresponding to b.
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intervention there was no change in lung function, whereas scores for both the Asthma Control
Questionnaire-6 (ACQ6) and Asthma Quality of Life Questionnaire (AQLQ) significantly improved by
more than the clinically important difference of 0.5 (ACQ6 mean difference −0.7, 95% CI −1.3 to −0.1,
p=0.03; AQLQ mean difference 0.8, 95% CI 0.1 to 1.5, p=0.03) (table 2).
The median time between baseline and follow-up biopsies was 28 days (range 14–56 days). A
representative bronchial biopsy is shown in figure 4a. There was a reduction in median ASM mass from
12% (interquartile range (IQR) 6–17) pre-BT to 6% (IQR 1–10) post-BT (median difference 5%, IQR
0–10, Wilcoxon p=0.03; figure 4b). The median relative reduction in ASM mass was 58% (IQR 6–90).
There was also a significant improvement in median epithelial integrity from 29% (IQR 15–40) pre-BT to
46% (IQR 25–56) post-BT (median improvement 14%, IQR 6–29, p=0.007; figure 4c, d). The median
relative increase in epithelial integrity was 56% (IQR 19–120).
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FIGURE 3 Airway temperature heterogeneity across bronchial generations and heating scenarios. Heating patterns a) at the lowest end of
bronchial thermoplasty (BT) applicability (luminal radius of 1.5 mm); b) for a midrange airway (luminal radius of 2.2 mm, corresponding to figure
2b, d) with impeded luminal evaporative cooling (e.g. occluded with a bronchoscope); and c) for a larger airway (luminal radius of 4.4 mm).
d) Thermal dynamics of an airway wall after the end of a single BT activation (marked by vertical dashed line) for the reference case of figure 2
(solid and dashed) and for the case of absent tissue perfusion and evaporative cooling (dotted lines). e, f ) Temperature distributions at 10 s (e)
and 12 s (f ), corresponding to the case of absent volumetric tissue cooling.
TABLE 1 Quantification of simulated thermal impact of bronchial thermoplasty at the end of an
activation cycle
Intermediate conducting airway# Large conducting airway¶
Baseline Occluded (no evaporative
cooling)
Mean wall temperature °C 59 59 50
Wall area fraction heated >65°C % 3 2 1
Wall area fraction heated >60°C % 43 35 7
Wall area fraction heated >55°C % 93 100 25
#: inner radius 2.2 mm, outer radius 3.5 mm; ¶: inner radius 4.4 mm, outer radius 5.7 mm.
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There was a numerical but nonsignificant reduction in the number of sub-epithelial myofibroblasts
(pre-BT median 25 cells·mm−2, IQR 7–47 versus post-BT median 13 cells·mm−2, IQR 6–21; p=0.17).
There was a significant inverse correlation between the change in ASM mass and myofibroblast count in
the lamina propria following BT (Spearman r=−0.55, p=0.046; figure 4e). Change in epithelial integrity
did not correlate with change in myofibroblast count nor ASM mass following BT (data not shown).
Improvements in AQLQ score did not correlate with pre-BT epithelial integrity, ASM mass or myofibroblast
number in the lamina propria nor with post-BT change (data not shown). Only three subjects had an
improvement ⩾1.0 thus no responder analysis was undertaken. Pre-BT epithelial integrity, ASM mass and
myofibroblast number in the lamina propria were not related to change in ACQ6 score (data not shown).
The change in ACQ6 score was inversely related to the change in ASM mass (Spearman r=−0.67, p=0.018),
but not with epithelial integrity (r=−0.03, p=0.09) or myofibroblast number in the lamina propria (r=0.41,
p=0.18). Five subjects had an improvement in ACQ6 score ⩾1.0. Compared with subjects not showing this
improvement in ACQ6, these five subjects had a small increase in ASM mass post-BT (median 2%, IQR −2
to 8 versus median −10%, IQR −8 to −12; p=0.003). This was in contrast to a higher pre-BT myofibroblast
number in the lamina propria (59 cells·mm−2, IQR 36–84 versus 7 cells·mm−2, IQR 3–43; p=0.03) and
greater decrease post-BT (37 cells·mm−2, IQR 30–51 versus −8 cells·mm−2, IQR 3 to −27; p=0.048). Those
with both an increase in ASM mass and a decrease in myofibroblast number in the lamina propria had the
greatest improvement in ACQ6 score compared with those that either had a decrease in both or a decrease
in ASM mass and increase in myofibroblast number (figure 4e).
Discussion
We have developed an integrated in vitro and in silico framework to model the acute effects of BT on ASM
and epithelial cells. In this framework, the in silico mathematical model serves as a “bridge” between the in
vitro and in vivo thermal effects, which are inaccessible by other means. The in vitro model identified a
sharp threshold in the response of both hBEC and ASM cells to heating. In vitro hBEC and ASM cell
number decreased significantly after the addition of media heated to ⩾65°C. Importantly, taking into
account the heat loss over 10 s in the in vitro experiments, these cells were exposed to a mean temperature
of 58–59°C. The mathematical model predicted a localised and highly heterogeneous heating pattern that
is very sensitive to airway calibre, with a relatively small fraction of the bronchial wall heated to >60°C in
all but the smallest airways (see also [25]). The integrated in vitro and in silico model predictions were
tested against in vivo bronchial biopsies taken pre- and post-BT. The biopsy samples showed an increase in
epithelial integrity and a reduction in ASM mass after BT.
Although greater than predicted based on our mathematical model, the observed post-BT relative median
reduction in ASM mass of 58% was consistent with previous clinical studies [13–16]. To explain this level
of ASM reduction by acute thermal injury alone, most of the airway wall in the calibre of airways sampled
at bronchoscopy would need to be heated to ⩾60°C. Thus, if the in vitro and in silico predictions are
correct, the difference must be due to an alternative biological mechanism triggered in response to BT,
such as the active thermal bystander effect [26].
TABLE 2 Baseline and follow-up (median time of 28 days) clinical characteristics of patients
undergoing thermoplasty and biopsy
Characteristic Baseline Follow-up p-value
Subjects n 14 –
Female sex n 9 –
Age years 52±13 –
GINA classification 5 n 9 –
BMI kg·m−2 31±8 –
Exacerbations in last 12 months n 4±3 –
Pre-BD FEV1 % predicted 68±19 67±20 0.5
Post-BD FEV1/FVC % 63±12 63±12 0.8
Bronchodilator reversibility % 19±11 16±12 0.5
ACQ6 score 3.1±1.6 2.5±1.7* 0.03
AQLQ score 3.4±1.7 4.1±1.8* 0.03
Data are presented as mean±SD, unless otherwise indicated. GINA: Global Initiative for Asthma; BMI: body
mass index; BD: bronchodilator; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; ACQ6:
Asthma Control Questionnaire-6; AQLQ: Asthma Quality of Life Questionnaire. *: paired t-test p<0.05
compared to baseline.
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Our in vivo biopsies showed significantly improved epithelial integrity after BT, which likely reflects
epithelial repair in response to thermal injury. Indeed, our in vitro data show evidence of acute phase
epithelial repair in response to heat. Others studies have not found changes in the epithelial phenotype in
biopsies obtained 3 months after completion of BT treatment, but have reported other effects upon
collagen deposition and bronchial nerves [16]. Although in this small study a reduction in ASM mass did
not correlate with increased epithelial integrity, whether epithelial repair might impact on other changes in
airway wall structure, including ASM mass, following BT warrants further investigation.
Myofibroblast numbers are increased in the lamina propria in patients with asthma and they traffic to sites
of injury, differentiate and promote wound repair [27–29]. We considered whether BT might affect the
number of myofibroblast cells in the lamina propria, and whether the prevalence of these cells might relate
to changes observed in the epithelium and ASM. We identified a numerical but nonsignificant reduction
in the overall number of myofibroblasts in the lamina propria in response to BT. However, there was a
significant inverse correlation between the change in ASM mass and myofibroblast number after BT. This
might represent a dynamic relationship between myofibroblasts and the ASM bundle, with migration of
myofibroblasts to and from the ASM bundle. Despite the small number of subjects in our study, we were
able to explore the relationship between the effects of BT on ASM mass, epithelial integrity and
myofibroblast numbers in the lamina propria and asthma-related symptoms assessed 6 weeks after the last
BT intervention. Surprisingly we found that improvement in asthma control was inversely related to
post-BT change in ASM mass, and that improvement in asthma control was greatest in those with an
increase in ASM mass and a reduction in myofibroblast number. The observed epithelial repair was not
associated with improved asthma control, but whether epithelial repair contributes to the reduced
exacerbation rates observed in larger studies after BT needs to be further investigated.
Our study had a number of potential limitations. The in vitro studies could not fully recapitulate the
behaviour of the ASM cells and bronchial epithelial cells in vivo because the heated media was added
directly to specific cell types in isolation. They also did not take into account asthmatic versus
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https://doi.org/10.1183/13993003.01680-2017 8
ASTHMA | I.L. CHERNYAVSKY ET AL.
non-asthmatic cellular phenotype, cell–cell interactions or the presence of submucosal tissue. In addition,
there was a small amount of heat loss over the 10-s exposure in the model system. However, our in vitro
data were very consistent across different methodological approaches and between two centres.
The mathematical model involved a number of simplifying assumptions. We modelled an airway and
surrounding parenchyma as a cross-section and neglected three-dimensional effects. This approximation is
justified by the relatively long (∼5 mm) length of the electrode compared to the airway wall thickness
(∼1 mm). The computational model also used averaged homogeneous electrothermal material properties
of the airway wall and parenchymal tissues and did not account for possible anatomo-physiological
variations within and between treated individuals. There was also the possibility of inherent operator
variability, patient lung movement and complex automatic controller safeguards incorporated into the BT
protocol, which were not included in the model. We have, however, tested the robustness of the in silico
model and quantified the uncertainty associated with model predictions via 1) appropriate mesh
convergence tests, 2) application of random spatial perturbations in tissue material properties (results not
shown) and 3) a comprehensive parameter sensitivity analysis. Indeed, the sensitivity analyses showed that
model predictions remained unaffected by a moderate level of variability in tissue material properties,
whereas airway wall and luminal morphometry had the greatest impact on the model. Nonetheless, the
developed mathematical modelling framework is intended to provide a qualitative rather than quantitative
insight into the impact of BT. Thus, notwithstanding the limitations of the in vitro and in silico modelling,
we are confident that these data do not support the concept of substantial acute loss of ASM mass as a
direct response to the heating effect of BT in the airways sampled at bronchoscopy.
There were also shortcomings in the BT in vivo clinical trial. First, the in vivo bronchial biopsies were
taken from the right upper lobe at baseline and the right lower lobe following BT, and the ASM mass at
baseline was lower than we have previously reported [24]. It is possible that some of the changes
demonstrated were due to variability in baseline remodelling between lung lobes, and variability in subject
selection in this cohort compared to others. We also observed a high degree of inter-patient variability in
the ASM response to BT. However, despite these factors, the observed overall magnitude of ASM mass
reduction was similar to that given in previous reports, giving confidence to the likelihood of the observed
changes being genuine. Finally, our BT in vivo study was too small to determine whether the observed
changes in airway remodelling relate to future clinical risk such as exacerbations. Determining this requires
either a large prospective study or a meta-analysis of the reported BT biopsy studies.
In conclusion, our in vivo data support a reduction in ASM mass in bronchial biopsies obtained post-BT
but our combined in vitro and in silico modelling suggest that the extent of this reduction in ASM mass
cannot be entirely explained by a direct acute effect of thermal injury on ASM following BT. Although we
cannot exclude the possibility that peri-procedural prednisolone contributed to remodelling, prednisolone
was administered prior to all procedures and, importantly, its effects on the epithelium are inconsistent
and no effects on the ASM mass have previously been reported [30]. Our data therefore challenge the
current concepts of the potential mechanisms of BT, indicating that an alternative mechanism(s) besides
direct thermal injury may contribute to this process. Epithelial integrity was also shown to increase in
response to BT, and post-BT myofibroblast number in the lamina propria was inversely related to ASM
mass. Whether epithelial repair in response to thermal injury and/or the dynamic interaction between the
ASM and myofibroblasts have consequent effects upon BT-associated reduced ASM mass remains to be
confirmed. Whether the BT protocol can be optimised to target specific airways or elements of airway
remodelling, perhaps in combination with patient-specific modelling to facilitate precision medicine, needs
to be studied.
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